Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Donepezil placebo Clear all
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

NCT01495195
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
High-dose donepezil, Low-dose donepezil, Selegiline, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil

NCT00829816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Alamitos, California • National City, California • Delray Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

NCT00006349
View directory record Official record
Conditions
Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions
vitamin E, donepezil hydrochloride, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 28, 2026, 2:50 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

NCT00754013
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (Donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Results available

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

NCT06285240
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1167, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hallandale, Florida • Decatur, Georgia • Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, ABT-126, donepezil
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 28, 2026, 2:50 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

Detecting an Early Response to Donepezil With Measures of Visual Attention

NCT03073876
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

NCT01466088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

NCT00884507
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, RO5313534
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Orange, California • Torrance, California • Norwalk, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

NCT00165737
View directory record Official record
Conditions
Dementia, Vascular
Interventions
Donepezil Hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
41 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
Hot Springs, Arkansas • St. Petersburg, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

NCT00151398
View directory record Official record
Conditions
Alzheimer Disease
Interventions
lecozotan SR, Donepezil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Study of Donepezil in Fragile X Syndrome

NCT01120626
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
donepezil, sugar pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period

NCT00586196
View directory record Official record
Conditions
Delirium
Interventions
donepezil, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
70 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 28, 2026, 2:50 PM EDT
Not listed Phase 3 Interventional

Enhancing Rehabilitation After Stroke

NCT00868010
View directory record Official record
Conditions
Ischemic Stroke
Interventions
donepezil, placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Warren, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil

NCT01406145
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ASP0777, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
San Diego, California • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Memory and Mental Health in Aging

NCT02988908
View directory record Official record
Conditions
Memory
Interventions
Donepezil, Placebos
Drug
Lead sponsor
Stanford University
Other
Eligibility
55 Years to 90 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

NCT00478205
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Donepezil on Gait and Balance in Parkinson's Disease

NCT01521117
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9

NCT00015132
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Sertraline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

NCT01677754
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Anaheim, California • Fullerton, California • Lomita, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 28, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 28, 2026, 2:50 PM EDT